Good evening. Here's what's moving in the world of medical cannabis today.
New analysis finds opioid overdoses decline after cannabis legalisation
A fresh analysis published this week by NORML has added to the growing body of evidence that legal cannabis access is associated with reductions in opioid-related harm. The review examined data from multiple US states and found that opioid overdose rates consistently decreased following the enactment of medical or adult-use cannabis legalisation laws.
Researchers described the findings as "adding to the already robust evidence documenting the opioid-sparing effects of cannabis". The analysis highlights the potential for legal cannabis access to mitigate the public health burden linked to both prescription and non-prescription opioid use. The study did not specify a precise percentage reduction but emphasised a statistically significant trend across jurisdictions.
Global cancer workforce crisis could strain healthcare systems by 2050
A report published by The Guardian today warns that the world faces a shortfall of 100 million healthcare staff by 2050, as 100,000 people are diagnosed with cancer every day. Researchers caution that healthcare systems risk being overwhelmed unless urgent investment in workforce planning is made.
While not directly about medical cannabis, the report has implications for the sector. As cancer incidence rises, demand for symptom management — including cannabis-based therapies for pain, nausea, and appetite loss — is likely to increase. The UK's medical cannabis sector, already struggling with limited NHS prescribing and access barriers, may face additional pressure if oncology services become further stretched.
Genomic test could spare millions of breast cancer patients chemotherapy
A groundbreaking trial reported by The Guardian suggests that a genomic test can identify breast cancer patients who can safely forgo chemotherapy and be treated with hormone therapy alone, with near-identical outcomes. The finding could spare millions of women the side effects of chemotherapy each year.
For the medical cannabis community, this development is relevant because chemotherapy remains a primary driver of demand for cannabis-based supportive care. If fewer patients require chemotherapy, the immediate need for cannabis to manage chemotherapy-induced nausea and pain may shift — though cannabis use for hormone therapy side effects and long-term symptom management is likely to remain significant.
US healthcare report card shows poor outcomes despite high spending
The Commonwealth Fund's 2026 report card on US healthcare, covered by The Guardian, finds that the United States spends 18 per cent of its economy on healthcare — nearly double the average of 19 comparable wealthy nations — yet achieves worse health outcomes. The report measures the US against peer countries across multiple metrics including access, equity, and efficiency.
This context is important for medical cannabis policy observers. Despite high spending, the US healthcare system's shortcomings have driven many patients to seek alternative treatments, including medical cannabis. The report's findings reinforce arguments from patient advocacy groups that cannabis access should be integrated into mainstream care pathways, particularly in a system where cost and access barriers are pronounced.
